Pharmaceuticals

Rx-360 Expands Trademark Portfolio to Japan

PHILADELPHIA, July 10, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium has now expanded their trademark registration for Joint Audit Program® logo to now include Japan.  Through the achievement of this milestone, Rx-360 has secured trademark registration for Rx360 and the J...

2023-07-10 18:00 2647

Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon

JAKARTA, Indonesia, July 10, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned Pharmaceutical company, is collaborating with MIT Hacking Medicine to address urgent healthcare challenges in the region by holding the first-everBio Farma x MIT Hacking Medicine Ha...

2023-07-10 15:19 3913

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fu...

2023-07-10 10:24 3383

Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years

SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized onJune 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years. This prestigious sub-lis...

2023-07-07 19:43 6250

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received ...

2023-07-07 15:52 4437

CARING PHARMACY CELEBRATES UNIFIED CARING MEMBERSHIP PROGRAMME WITH GEORGETOWN PHARMACY AND WELLINGS PHARMACY

KUALA LUMPUR, Malaysia, July 6, 2023 /PRNewswire/ -- CARiNG Pharmacy, Georgetown Pharmacy, and Wellings Pharmacy, all subsidiaries under CARiNG Pharmacy Group, are proud to announce their newly revamped Caring Membership Mobile App which unifies all 3 pharmacies' membership programme into one. To...

2023-07-06 18:00 4600

MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea

SEOUL, South Korea, July 6, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced its ultra-high-throughput genetic sequencer DNBSEQ-T7 received the medical device registration certificate from the Korea Ministry of...

2023-07-06 09:00 4167

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...

2023-07-06 07:25 5009

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...

2023-07-06 07:19 5580

AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES

BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), is now available to patients inthe United States after five years of experien...

2023-07-04 01:22 3088

Henlius Forecasts Profit in 1H 2023

Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...

2023-07-03 18:59 6052

SHL Medical acquires 100% of the shares in Swiss company LCA Automation

SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical's response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcomingSwiss man...

2023-07-03 17:00 4552

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma

ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-07-03 08:00 6475

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

* Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based inRiyadh. * JV focuses on providing state-of-the-art multiomic testing services to patients, health system...

2023-07-02 14:00 4732

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023

* 64 patients with CLDN18.2 positive G/GEJ cancer were enrolled in TranStar102 (TST001-1002). CLDN18.2 positivity is defined as ≥10% tumor cells with ≥1+ intensity. These patients represent approximately 55% of all G/GEJ adenocarcinomas. The overall median PFS was 9.5 months with no differences...

2023-06-30 17:33 4037

CPHI & PMEC China 2023 to launch international roadshow in Guangzhou

China's booming Pearl River Delta, a key pharma manufacturing hub, sees rapid internationalisation SHANGHAI, June 29, 2023 /PRNewswire/ -- CPHI & PMEC China will open a special roadshow to be hosted at the PWTC Expo (4-6 September, 2023) in the city of Guangzhou (Guangdong Province). The new add...

2023-06-29 18:10 3319

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment SINGAPORE, June 29, 2023 /PRNewswire/ -- Biosyngen, an immune-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the of...

2023-06-29 17:14 5031

Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA),  has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructi...

2023-06-28 17:07 6518

First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed

* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S andChina. * The first human patients were dosed with the drug. * This is a potentially first-in-class an...

2023-06-27 21:00 5762

Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership

SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics. As leaders in their respective...

2023-06-27 15:33 5420
1 ... 108109110111112113114 ... 184